Company Information

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Kitov’s pipeline currently features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. Lowering development risk and cost through streamlined regulatory approval of novel late-stage therapeutics, Kitov delivers rapid ROI while making a meaningful impact on people’s lives. 

Read More

Price Data
NASDAQKTOV
Recent News
Aug 16, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial results for the first half of...

Jul 31, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and...

Jul 18, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, today announced results of a pre-clinical study demonstrating that NT-219, the lead drug...

More >


print email